Theme:Strategy for Clinical Trial in Personalized Medicine
Greeting
 |
Osamu Nagayama, Chairman
Chugai Academy for Advanced Oncology |
Opening Remarks
 |
Bruce Chabner, MD
Director of Clinical Research, Cancer Center
Massachusetts General Hospital, Boston Massachusetts |
▶ Symposium 1 Personalized medicine; Targeting ALK-fusion
 |
- Chair:
- Hiroyuki Mano, MD, PhD
- Jichi Medical University/Graduate School of Medicine, The University of Tokyo, Japan
Nagahiro Saijo, MD, PhD
- Kinki University, School of Medicine, Japan
|
 |
- Speaker:
- Hiroyuki Mano, MD, PhD
Professor of Medicine, Department of Medical Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo
Professor of Medicine, Division of Functional Genomics, Jichi Medical University, Tochigi
|
 |
- Speaker:
- Kengo Takeuchi, MD, PhD
Project leader / Senior staff scientist, Pathology Project for Molecular Targets /Division of Pathology, The Cancer Institute Japanese Foundation for Cancer Research
|
 |
- Speaker:
- Pasi Antero Jänne, MD, PhD
Associate Professor of Medicine, Dana-Farber Cancer Institute, USA
|
 |
- Speaker:
- A. John Iafrate, MD, PhD
Associate Pathologist, Massachusetts General Hospital
Associate Professor of Pathology, Department of Pathology, Harvard Medical School, USA
|
▶ Symposium 2 Synthetic lethality; Theory and Practice
 |
- Chair:
- Kiyohiko Hatake, MD, PhD
- Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan
Yuko Kitagawa, MD, PhD
- Keio University School of Medicine, Japan
|
▶ S2-1. Some practical issues related to shRNA/siRNA screens in mammalian cells(cancelled)
|
- Speaker:
- William Kaelin, MD
Professor of Medicine, Harvard Medical School
Division of Medical Oncology/Molecular and Cellular, Dana-Farber Cancer Institute, USA
|
 |
- Speaker:
- Christopher Lord, PhD
Senior Staff Scientist, The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, UK
|
“The Methodological Challenge of delivering personalised therapy for cancer patients”
  |
- Chair:
- Kiyohiko Hatake, MD, PhD
Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan
Nobuyuki Mizunuma,MD
Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan
- Speaker:
- Patrick G. Johnston, MD, PhD
Dean, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University BelfastDirector, Institute of Health & Life Sciences, Queen’s University Belfast, UK
|
▶ Symposium3 Therapeutic Inhibition of oncogenic signaling
 |
- Chair:
- Masakazu Toi, MD, PhD
- Kyoto University School of Medicine, Japan
Chikashi Ishioka, MD
- Tohoku University School of Medicine, Japan
|
 |
Speaker:
Jose Baselga, MD, PhD
Professor, Department of Medicine, Harvard Medical School
Associate Director, MGH Cancer Center, Medicine, Massachusetts General Hospital
Chief, Hematology/Oncology, Medicine, Massachusetts General Hospital, USA
|
 |
- Speaker:
- David B. Solit, MD
Elizabeth and Felix Rohatyn Chair for Junior Faculty, Memorial Sloan-Kettering Cancer Center, USA
|
 |
- Speaker:
- Neal Rosen, MD, PhD
Enid A. Haupt Chair in Medical Oncology
Member, Department of Medicine
Member, Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, NY
Professor of Pharmacology, Cornell University Graduate School of Medical Sciences, New York, NY
Professor of Medicine, Joan and Sanford I. Weill Medical College, Cornell University, New York, NY, USA
|
Closing
 |
Makoto Ogawa, MD
Emeritus President, Aichi Cancer Center, Japan |